Research programme: antigen inserted alpha virus like particle vaccines - VLP Therapeutics

Drug Profile

Research programme: antigen inserted alpha virus like particle vaccines - VLP Therapeutics

Alternative Names: iα-VLP - VLP Therapeutics; VLPM01

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VLP Therapeutics
  • Developer Georgetown University; Institute of Tropical Medicine, Nagasaki University; VLP Therapeutics
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria
  • Research Autoimmune disorders; Cancer; Dengue; Infections

Most Recent Events

  • 13 Oct 2017 VLP Therapeutics receives Small Business Innovation Research grant from National Cancer Institute, USA for vaccine-based immunotherapy development in Cancer
  • 05 Oct 2016 VLP Therapeutics receives grant from Global Health Innovative Technology Fund for Dengue vaccine development in Japan
  • 14 Jul 2016 VLP Therapeutics receives Peer Reviewed Medical Research Program Technology/Therapeutic Development grant from the United States Department of Defense for Malaria vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top